The Past, Present, and Future of Non-Viral CAR T Cells
Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology that has revolutionized the way we conceive immunotherapy. The impressive clinical results of complete and prolonged response in refractory and relapsed diseases have shifted the landscape of treatment for he...
Main Authors: | Alex Moretti, Marianna Ponzo, Charles A. Nicolette, Irina Y. Tcherepanova, Andrea Biondi, Chiara F. Magnani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.867013/full |
Similar Items
-
CAR NK-сells for the treatment of hematological malignancies: A review
by: Irina V. Gribkova
Published: (2022-11-01) -
Adaptor CAR Platforms—Next Generation of T Cell-Based Cancer Immunotherapy
by: Claudia Arndt, et al.
Published: (2020-05-01) -
Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
by: Stefan Stoiber, et al.
Published: (2019-05-01) -
Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors
by: Francesco Boccalatte, et al.
Published: (2022-10-01) -
The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: Moderate is better
by: Rui Mao, et al.
Published: (2022-10-01)